Abstract
Presentation Description :
An important link between P2X7 receptor (P2X7R) and inflammation has been demonstrated indicating this receptor as potential pharmacological target in diabetic retinopathy.
P2X7R emerges as attractive pharmacological target to handle the early phase of diabetic retinopathy by using P2X7R antagonists.
Data generated from in silico and in vitro study will be presented. In particular, an in silico study to characterize the molecular features of selective P2X7 antagonists, and an in vitro study to assess novel P2X7 ligands will be discussed.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.